59615 Development of Patient Derived Glioblastoma Organoid and Primary 3D Models

View at publisher Summarise with VIRAT
Authors: Evangelos Liapis, Wenge Li, Martha C. Salas, Adele Asia Ponzoni, Elizabeth E. Ginalis, Linda Szymanski, Kar Chow, Kangmin D. Lee, George J. Kaptain, Benjamin Tycko, Claire L. Carter
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Patient-derived 3D models of glioblastoma are being utilized in precision medicine for both function studies and pharmacokinetic/pharmacodynamic investigations as they are more clinically relevant. To-date, there are limited numbers of patient-matched 3D models that recapitulate the heterogeneity of the tumor microenvironment. This has hindered the development of more effective treatment options for this deadly tumor. METHODS: Five patients underwent craniotomies for glioblastoma resection. Tumor tissue samples were collected from fluorescing and non-fluorescing regions based on fluorescein sodium dye from multiple distinct brain locations. Of the tissues dissected, several samples were snap frozen, and the remainder were designated to organoid and primary cell line propagation. Frozen samples and cell models were characterized using histopathology, mass spectrometry imaging, RNA sequencing, and nanopore sequencing. Low, medium, and high passages of organoids and 3D spheroid models were assessed for genomic drift using nanopore sequencing and pathology. Drug screening of patient-derived organoids and spheroid models were carried out using standard protocols for 3D models. Statistical measurements were performed using GraphPad Prism. IC50 were calculated with non-linear regression analysis. RESULTS: Successful propagation of glioblastoma primary models was not dependent on the tumor location. Several organoid and primary 3D cell models were successfully propagated from up to four different tumor locations within a single patient sample, including fluorescing and non-fluorescing microenvironments. Genomic profiles validated the models with their patient-matched phenotypes. Ongoing studies are evaluating success vs failure of model propagation with histopathological characteristics. CONCLUSIONS: We have developed and validated several new primary glioblastoma models that recapitulate the different tumor microenvironments with each sample’s corresponding radiographic locations obtained using intraoperative navigation with the patient’s preoperative MRI.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Cancer Cells and Metastasis Mathematical Biology Tumor Growth

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
307–307
Publication date
26 March 2026
Language
EN